Profound Medical Corp · TSX:PRN
Profound Medical — Q1 2026 Earnings Presentation
29 slides from Profound Medical's earnings presentation, May 7, 2026
Slide 1: Precision Surgery without incision
Precision Surgery without incision © 2025 PROFOUND MEDICAL CORP. C ORP ORA TE P RE S EN T AT ION May 2026 NASDAQ: PROF | TSX: PRN
Slide 2: Forward-Looking Information
2 Forward-Looking Information Certain statements in this presentation may contain certain information that is “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws with respect to Profound Medical Corp. (“Profound” or the “Company”). Such stat
Slide 3: Market & Industry Data
3 NASDAQ: PROF | TSX: PRN Market & Industry Data Market data and industry forecasts contained in this presentation have been obtained from industry publications, various publicly available third-party sources and subscription-based reports as well as from management’s good faith estimates, which are
Slide 4: Grow Topline with TULSA-PRO & Opportunistically Advance Sonalleve
4 Grow Topline with TULSA-PRO & Opportunistically Advance Sonalleve NASDAQ: PROF | TSX: PRN Primary Investment Incremental Investment CORPORATE PRESENTATION Precision Ablative treatment of Precision Ablative treatment of prostate FDA Indication: Thermal ablation of Adenomyosis and Uterine Fibroid Sh
Slide 5: Prostate Cancer: The Unmet Need
5 Prostate Cancer: The Unmet Need Over 300,000 U.S. PCa cases Prostatectomy Outcomes: each year NASDAQ: PROF | TSX: PRN Prospective Multicenter Comparison of Open vs Robotic Prostatectomy: The PROST-QA/RP2 Consortium Peter Chang, Andrew A. Wagner, Meredith M. Regan et al. Radical Prostatectomy Radia
Slide 6: The TULSA Procedure
6 The TULSA Procedure NASDAQ: PROF | TSX: PRN CORPORATE PRESENTATION https://profoundmedical.com/wp-content/uploads/2025/05/106885B-TULSA-PRO-3D-ANIMATION-compressed.mp4
Slide 7: 70+ Peer-Reviewed Publications & 200+ Conference Presentations
7 70+ Peer-Reviewed Publications & 200+ Conference Presentations Clinical Evidence in Unrivaled Variety of Prostate Indications Partial Gland Ablation Whole Gland Ablation NASDAQ: PROF | TSX: PRN Benign Organ Confined Prostate Cancer Salvage / Palliative Large prostate BPH, Hybrids with low grade Le
Slide 8: The Value Proposition — Physician
8 The Value Proposition — Physician Very relaxed procedure, with practice 4 treatments per day, with AI software in the works - 6 per day will be possible. Weekly TULSA day – mix and match patients' whole gland, partial gland, hybrid, focal, BPH, salvage. NASDAQ: PROF | TSX: PRN Higher RVU’s per uni
Slide 9: The Value Proposition — Patients
9 The Value Proposition — Patients Versatile technology – customized treatment, clinical outcome durability, reduced side effects. Go home in an hour after the procedure, no blood loss, minimal pain. NASDAQ: PROF | TSX: PRN CORPORATE PRESENTATION TULSA Patient Robotic Prostatectomy With family 24 ho
Slide 10: TULSA – Autonomous Robotics For Whole-Gland or Partial/Focal Ablation
10 TULSA – Autonomous Robotics For Whole-Gland or Partial/Focal Ablation Whole-gland TULSA whole-gland or Focal therapies, typically NASDAQ: PROF | TSX: PRN treatments partial/focal procedure treat <25% of gland Robotic Laparoscopic CORPORATE PRESENTATION Prostatectomy High Intensity Focused Ultraso
Slide 11: The TULSA Energy Source and its Value
11 The TULSA Energy Source and its Value TULSA uses the least amount of energy 1 2 Fast, precise & gentle ablation for all prostates to kill tissue NASDAQ: PROF | TSX: PRN • Transurethral ultrasound, TULSA Heats tissue to 57°C 0.02 Kcal per cc focused to a blade and not a single point, heats a large
Slide 12: Award Winning TULSA AI Software
12 Award Winning TULSA AI Software Recognized for image-guided therapy innovation 1 Thermal Boost 2 Contouring Assistant NASDAQ: PROF | TSX: PRN Ablation confidence of high-risk features Manual Contouring: Contouring Assistant 2.0: • On-demand increase of target temperature to increase dose to • Tim
Slide 13: Growth Cycle for Interventional MR (iMRI) is Upon Us
13 Growth Cycle for Interventional MR (iMRI) is Upon Us https://www.siemens-healthineers.com/en-us/magnetic- https://www.cookmedical.com/divisions/imri/ resonance-imaging/high-v-mri/magnetom-free-max NASDAQ: PROF | TSX: PRN CORPORATE PRESENTATION Society of Interventional Radiology Conference – Apri
Slide 14: TULSA Technology's Unrivalled Flexibility To Ablate Prostate Tissue
14 TULSA Technology’s Unrivalled Flexibility To Ablate Prostate Tissue NASDAQ: PROF | TSX: PRN NEXT TA RG Whole Gland Ablation/Treatment E T ~80% of patients: • Robotic Prostatectomy (>20 yrs) Ablation of Enlarged Prostate • Radiation (>20 yrs; • Waterjet ablation (5 yrs) CORPORATE PRESENTATION alth
Slide 15: CAPTAIN (NCT05027477)
15 CAPTAIN (NCT05027477) NASDAQ: PROF | TSX: PRN Customized Ablation with TULSA vs. Prostatectomy in Intermediate-Risk Prostate Cancer CAPTAIN is an audacious trial that would be the first to generate Level 1 evidence demonstrating superior safety and non-inferior efficacy of ablative therapy vs. RP
Slide 16: CAPTAIN Trial Data: Eliminates Blood Loss & Overnight Stay
16 CAPTAIN TRIAL DATA: TULSA-PRO Eliminates Blood Loss & Overnight Stay for the Patient & Hospital NASDAQ: PROF | TSX: PRN From less blood loss to From shorter length of stay to No blood loss No overnight stay CORPORATE PRESENTATION p < 0.001 Dinner p < 0.001 0 1 2 Length of stay (days) Treatment Me
Slide 17: CAPTAIN Trial Data: Patients in Better Overall Health After Treatment
17 CAPTAIN TRIAL DATA: TULSA-PRO Patients are in Better Overall Health After Treatment NASDAQ: PROF | TSX: PRN Significantly better overall health during first month post treatment Change in EQ-5D-5L VAS overall health score after treatment TULSA Patients: Significantly less deterioration in Change
Slide 18: CAPTAIN Trial Data: 30–90 Day Recovery
18 CAPTAIN Trial Data: 30–90 Day Recovery NASDAQ: PROF | TSX: PRN 10% p < 0.05 TULSA 8% 6.3% RP p < 0.05 6% 10 (4 – 15) days 4% CORPORATE PRESENTATION 2% 1.6% 19 (10 – 41) days 0.7% 0.0% 0% Days before returning to work Hospitalization ICU admission Significantly less time missed Fewer admissions to
Slide 19: CAPTAIN Trial Data: Primary Safety Endpoint Met
19 CAPTAIN TRIAL DATA: Primary Safety Endpoint Met Urinary Continence & Primary Composite Endpoint NASDAQ: PROF | TSX: PRN Erections at 6 Months % preserving composite function 100 100 % preserving function TULSA p < 0.05, risk ratio = 2.1 75 75 TULSA TULSA: 50% RP RP 50 50 CORPORATE PRESENTATION RP
Slide 20: CAPTAIN Trial Data: Secondary Oncological Outcomes
20 CAPTAIN TRIAL DATA: Secondary Oncological Outcomes NASDAQ: PROF | TSX: PRN Surgical Pathology After RP pT2 pTx pT3a pT3 Pathologic Stage 30% 63% 2% 5% CORPORATE PRESENTATION 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Negative Positive Surgical Margins 67% 33% 0% 10% 20% 30% 40% 50% 60% 70% 80% 9
Slide 21: TULSA-PRO U.S. Market Opportunity
21 TULSA-PRO U.S. Market Opportunity PCa BPH / Hybrid NASDAQ: PROF | TSX: PRN Overgrow transition zone Cancerous tissue CORPORATE PRESENTATION ~200,000 ~400,000 1 Addressable 1 Addressable Cases Annually Cases Annually Average Average ~$8,000 ~$8,000 2 2 Procedure Price Procedure Price $1.6 Billion
Slide 22: 2026 U.S. Reimbursement, Final Rule
22 2026 U.S. Reimbursement, Final Rule TULSA Procedure Strongly Positioned Against Other Technologies NASDAQ: PROF | TSX: PRN Prostate Cancer Enlarged Prostate Prostate Disease Treatment & BPH Greenlight Therapy TULSA TURP HoLEP Aquablation RARP HIFU Cryo TURP CPT Code 55882 52601 52648 52649 52597
Slide 23: 2020–2024: Building a High-Quality Installed Base & Market Leadership
23 2020–2024: Building a High-Quality Installed Base & Market Leadership NASDAQ: PROF | TSX: PRN 1 Market Entry Strategy 2 Top-Tier Hospitals • Focus on opinion leaders, early adopters, Opinion leaders, validation, reimbursement imaging centers cost calculations, publications • Service provider busi
Slide 24: TULSA's Primary Competitive Positioning
24 TULSA’s Primary Competitive Positioning 1. Interventional MRI (iMRI) Movement has Started Short-term: TULSA compatible with ~5,000 installed MRs in the U.S.: less than ~200 needed to reach profitability NASDAQ: PROF | TSX: PRN Medium-term: TULSA + Siemens designed MRs for interventional procedure
Slide 25: TULSA-PRO Growth Strategy
25 TULSA-PRO Growth Strategy NASDAQ: PROF | TSX: PRN SHORT-TERM MID-TERM LONG-TERM Path to Profitability Exponential Growth Sustained Leadership 200 TULSA programs using Complete solution, Fully integrated TULSA + iMRI existing MR installed base advanced workflow platform positioned as the → ~$85M a
Slide 26: Building an Eco-System
26 NASDAQ: PROF | TSX: PRN B UIL DING AN ECO -SY STEM CORPORATE PRESENTATION SO NAL LEV E M R-H IFU Current Technology & Commercialization Strategy
Slide 27: Sonalleve MR-HIFU System (V2)
27 Sonalleve MR-HIFU System (V2) NASDAQ: PROF | TSX: PRN CORPORATE PRESENTATION Sonalleve tabletop connected to the scanner Compatible with Philips MRI
Slide 28: V2 Platform Technology: One System, Multiple Modes of Action and Clinical Applications
28 V2 Platform Technology: One System, Multiple Modes of Action and Clinical Applications NASDAQ: PROF | TSX: PRN Mode of Action Clinical Applications Pediatric Care: Regulatory Approved Applications Primary treatment US Osteoid osteoma Ablation • Tissue Destruction FDA HDE approval • Thermal Necros
Slide 29: Corporate Presentation
CORPORATE PRESENTATION NASDAQ: PROF | TSX: PRN 29